Insurance Solutions for Life Science Companies
Explore insurance solutions designed to support life science organizations at every stage of growth.
For small and midsize life science organizations, the risks associated with new federal medical device regulation are bigger than compliance alone, with potential impacts on liability, operational disruption and insurance exposure.
The United States Food and Drug Administration’s Quality Management System Regulation (QMSR) became effective on Feb. 2, 2026, aligning U.S. medical device requirements with ISO 13485:2016 — the international consensus standard for Quality Management Systems.
“It's more than just a regulatory update,” says Brad John, head of middle and large business life sciences at The Hartford. “It's really a shift in how medical device companies are expected to manage quality across the entire product life cycle and that means different things depending on where you are in that life cycle.”
Why QMSR Can Hit Growth-Stage Companies Harder
Larger, more mature manufacturers may already have quality systems closely aligned with ISO 13485, therefore starting from a stronger position. However, small and midsize life science companies may feel the QMSR more acutely as they are still building infrastructure while simultaneously trying to commercialize, expand manufacturing, manage third parties and prepare for growth.
“It ultimately raises the stakes in the day-to-day operations,” says Steven Maley, head of small business underwriting at The Hartford.
Documentation, supplier oversight, complaint handling, design controls, production processes and management responsibility all become part of a broader evidence trail.
“Larger companies have the scale and the infrastructure internally to tackle it, but smaller companies are often leaner in general,” adds John.
Companies who are slow or unable to adjust to the new standards could face downstream effects including:
- Product recalls
- FDA warning letters
- Product liability claims
- Business interruption effects
- Reputational harm
A quality system weakness can quickly become a business continuity event. A supplier deviation, validation gap or documentation failure may lead to a product hold, delayed release, recall or production shutdown. The resulting effects can extend beyond regulatory remediation to lost revenue, disrupted customer commitments, additional operating costs and delayed commercialization.
Documentation Is Key
When moving to the QMSR, companies should appreciate the importance of increased documentation throughout the lifecycle, as it will become the primary evidence that risk management, quality oversight and regulatory compliance are functioning as intended.
“You’ll need a significantly more robust level of documentation proving that processes are in place, even for processes that another entity is executing on your behalf,” says John.
Another issue is repeatability. As a company grows, weak controls can lead to deviations, validation gaps and other problems that become more than a pure compliance issue. With the appropriate documentation, a company can better prove the appropriate steps were taken, procedures were best in class and quality standards and protocol were followed.
Quality system failures may also create significant inventory and property-related costs. Raw materials, work in process or finished products may need to be quarantined, retested, reworked or destroyed. For a growth-stage company with limited inventory, long production lead times or dependence on a single product, these costs can disrupt revenue, delay a launch and undermine confidence among customers, distributors, investors and strategic partners.
Risk Transfer Changes
Even when a critical process is performed by a supplier, the legal manufacturer retains responsibility for ensuring risks are identified, controlled, monitored and documented. This understanding is crucial for smaller companies that often run lean and may depend on outside contractors and suppliers for everything from materials to payroll to procedures development.
“This requires companies to take greater responsibility for understanding and overseeing the quality standards of the third parties that support their operations,” says Maley.
Questions To Consider
Companies may want to ask themselves these questions to assess how prepared they may be or steps they need to take for implantation of the QMSR.
- Is your quality system built for the business that you have today or the business you had?
- Are documentation practices keeping pace with production and commercialization? If the FDA were to inspect your business today, can you quickly produce evidence of the protocols you use to stay compliant?
- What type of business interruption would you face if you were found in non-compliance? How can you manage the business cost associated with a recall?
- What percentage of your revenue depends on a single product or supplier?
- How will you validate that a supplier or a contract manufacturer is adhering to new standards?
Where Insurance Plays a Role
As life science companies mature, their insurance needs often become more complex. Risks that begin with research, laboratory operations and clinical activities may expand to include:
- Manufacturing
- Product liability
- Recall
- Property
- International
- Clinical
- Cyber
- Supply chain and business interruption
Insurance needs should evolve as the company evolves. A carrier with life sciences expertise can help companies assess changing risks, coordinate coverage across multiple lines and apply risk-management resources as operations become more complex.
The right carrier can provide insight based on data from their book of business to help with risk management consulting and site inspections. It can also provide risk engineering controls and help a company navigate moving into a midsize or large space.
“Companies need to talk to their insurance carrier and risk management advisor about the benefits and risks to scaling up, moving services in-house and adding products,” explains Maley. “Those things impact a lot of different lines and coverages and help structure the best options for that company — whether it's property coverage, product liability limits, product recall coverage, errors and omissions coverage or even cyber exposure — so they remain adequately protected.”
Learn more about insurance options for small, midsize and large-scale life science companies.
Related Articles
Legal & Regulatory
Coverage Gaps
How Life Science Companies Can Prepare for New EU Regulations
08/06/2025
7 min read
Legal & Regulatory
Regulatory Change
Bridging the Gap: Managing Shared Liability in Life Science and Healthcare
11/06/2025
6 min read
Legal & Regulatory
Regulatory Change
Navigating Blood Shield Laws in the Biomedical Industry
11/24/2025
5 min read